Funding for this research was provided by:
Received: 23 January 2022
Accepted: 11 July 2022
First Online: 16 July 2022
: Mark Stettner served on the scientific advisory boards and/or received speaker honoraria, travel funding or honoraria for medical writing from UCB, Biogen Idec; Grifols, Genzyme, Roche, Merck, Diamed, Kedrion, LFB, PPTA, Novartis, Octapharma, CSL Behring, Sanofi-Aventis, TEVA, and Bayer. Refik Pul has received honoraria for lecturing and consulting from Alexion, Bayer Healthcare, Biogen Idec, Bristol-Mayers Squibb, MedDay, Merck Serono, Mylan, Novartis, Roche, Sanofi-Aventis. He has received research fund from HERZ Burgdorf, Merck-Serono and Novartis. Karl Oettl has received the Albus Award by Grifols SA, Spain. Andreas Kribben has received grants for clinical studies, speaker’s fees, honoraria, and travel expenses from Actelion, Amgen, Amicus, Alexion, Astellas, Bayer, Baxter, Binding Site, Bristol Myers, Chiesi, CytoSorbents, Fresenius, GlaxoSmithKline, Hexal, Janssen, Kyowa Kirin, MSD, Novartis, Otsuka, Peripal, Pfizer, Roche, Sanofi, Shire, Teva, and Vifor Fresenius Medical. All other authors declare no conflict of interests.